Cargando…

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue is often not available. However, controver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knijn, N, Mekenkamp, L J M, Klomp, M, Vink-Börger, M E, Tol, J, Teerenstra, S, Meijer, J W R, Tebar, M, Riemersma, S, van Krieken, J H J M, Punt, C J A, Nagtegaal, I D
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065268/ https://www.ncbi.nlm.nih.gov/pubmed/21364579 http://dx.doi.org/10.1038/bjc.2011.26

Ejemplares similares

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
por: Mekenkamp, L J M, et al.
Publicado: (2010)

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010)

Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes
por: Thomson, A H, et al.
Publicado: (2016)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study
por: Horsch, M, et al.
Publicado: (2009)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
por: Deschoolmeester, V, et al.
Publicado: (2010)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Myofibroblast activation in colorectal cancer lymph node metastases
por: Yeung, T M, et al.
Publicado: (2013)

Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability
por: Kets, C M, et al.
Publicado: (2006)

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition
por: Hamidi, H, et al.
Publicado: (2014)

Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases
por: Goos, J A C M, et al.
Publicado: (2014)

Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer
por: Songun, I, et al.
Publicado: (2005)

A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens
por: Gonzalez de Castro, D, et al.
Publicado: (2012)

Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone
por: Aldridge, S E, et al.
Publicado: (2005)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Role of IL-12p40 in cervical carcinoma
por: Zijlmans, H J M A A, et al.
Publicado: (2012)

Inactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases
por: Teng, Y, et al.
Publicado: (2010)

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis
por: Goos, J A C M, et al.
Publicado: (2013)

Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases
por: Buckowitz, A, et al.
Publicado: (2005)

Expression of osteopontin coregulators in primary colorectal cancer and associated liver metastases
por: Mole, D J, et al.
Publicado: (2011)

Increased Dickkopf-1 expression in breast cancer bone metastases
por: Voorzanger-Rousselot, N, et al.
Publicado: (2007)

Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases
por: Kahlert, C, et al.
Publicado: (2014)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer
por: Kubben, F J G M, et al.
Publicado: (2006)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma
por: Sunaga, N, et al.
Publicado: (2014)

Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
por: de la Piedra, C, et al.
Publicado: (2013)

Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases
por: Gök, M, et al.
Publicado: (2011)

Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
por: Alcaraz, A, et al.
Publicado: (2013)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction
por: Lee, G T, et al.
Publicado: (2014)

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study
por: van Grieken, N C T, et al.
Publicado: (2013)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

High-risk HPV type-specific clearance rates in cervical screening
por: Bulkmans, N W J, et al.
Publicado: (2007)

Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo
por: Meijer, J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_5c2rr6qk73tnhqb5m9h714iaam